CYP2D6 polymorphism in relation to tramadol metabolism: A study of faroese patients

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 271-275

  Halling, Jónrit ^a,c   Weihe, Pál ^b   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP2D6 polymorphism; Faroe Islands; Pharmacokinetics; Steady state condition; Therapeutic drug monitoring; Tramadol

Indexed keywords

CYTOCHROME P450 2D6; SPARTEINE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DEMETHYLATION; DRUG METABOLISM; EUROPEAN UNION; FAROE ISLANDS; FEMALE; GAS CHROMATOGRAPHY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CONCENTRATING CAPACITY; MALE; PHENOTYPE; PLASMA; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; STEADY STATE; URINALYSIS; DENMARK; GENE FREQUENCY; GENETICS; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DENMARK; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRAMADOL;

EID: 47249099319     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181666b2f     Document Type: Article

References (29)

1. Frankus E, Friderichs E, Kim SM, et al. On separation of isomeres, structural elucidation and pharmacological characterization of 1-(mmethoxyphenyl)-2-(dimethylaminomethyl)-cyclohexan-1-ol [in German]. Arzneimittelforschung. 1978;28:114-121.
2. Dayer P, Desmeules J, Collart L. Pharmacology of tramadol [in French]. Drugs. 1997;53(Suppl 2):18-24.
3. Borlak J, Hermann R, Erb K, et al. A rapid and simple CYP2D6 genotyping assay: case study with the analgetic tramadol. Metabolism. 2003;52:1439-1443.
4. Potschka H, Friderichs E, Loscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000;131:203-212.
5. Musshoff F, Madea B, Stuber F, et al. Enantiomeric determination of tramadol and O-desmethyltramadol by liquid chromatography-mass spectrometry and application to postoperative patients receiving tramadol. J Anal Toxicol. 2006;30:463-467.
6. Lintz W, Erlacin S, Frankus E, et al. Biotransformation of tramadol in man and animal [in German]. Arzneimittelforschung. 1981;31:1932-1943.
7. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001;29:1146-1155.
8. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1993;260:275-285.
9. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879-923.
10. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997;54:643-652.
11. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996;60: 636-644.
12. Gillen C, Haurand M, Kobelt DJ, et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:116-121.
13. Lai J, Ma SW, Porreca F, et al. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol. 1996;316:369-372.
14. Paar WD, Poche S, Gerloff J, et al. Polymorphic CYP2D6 mediates Odemethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53:235-239.
15. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther. 2005;77:458-467.
16. Pedersen RS, Brosen K, Nielsen F. Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine: application to clinical studies. Chromatographia. 2003; 57:279-285.
17. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005; 77:312-323.
18. Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects: the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol. 2005;61:257-266.
19. Eichelbaum M, Spannbrucker N, Steinke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979;16:183-187.
20. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977;2:584-586.
21. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3: 229-243.
22. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39:533-537.
23. Halling J, Petersen MS, Damkier P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005;61:491-497.
24. Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol. 2008;65:134-138.
25. West J. Faroe: The Emergence of a Nation. London: Hurst; 1972.
26. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105:231-238.
27. Vinks A, Inaba T, Otton SV, et al. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther. 1982;31:23-29.
28. Brosen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol. 1985;57:357-360.
29. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31:347-353.